Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Liverpool to be Global Cancer Research Hub

19.10.2006
Liverpool is to benefit from a multi-million pound development in cancer services and research activity with the merger of Merseyside’s three biggest cancer service providers.

The University of Liverpool, the Royal Liverpool University Hospital (RLUH) and the Clatterbridge Centre for Oncology (CCO) are combining their cancer resources and facilities to provide better quality treatments for a broader range of cancers including head and neck, lung and lymphoma and enable international clinical trials of new cancer therapies.

It is planned that the merger will lead to the establishment of a Liverpool Experimental Cancer Medicine Centre (LECMC) to facilitate global clinical trials of new cancer therapies at their earliest stages (Stage I and II). This will allow for new drugs to be tested on a small group of patients, before being trialled with larger groups and internationally.

The centre, which will be funded by £750,000 from Cancer Research UK, will include the addition of six beds for cancer patients at RLUH to participate in cancer drugs trials as well as a new Chair of Medical Oncology, who will oversee the trials and related cancer research projects. The LECMC’s resources will also be accessible to external users in science and industry.

The LECMC will also be supported by a £1.1million transfer of six leading cancer specialists from the Clatterbridge Cancer Research Trust on Wirral to the University of Liverpool Cancer Research Centre (ULCRC). The team, led by Professor Ross Sibson, will work on cancer studies in areas such as breast cancer and neurological malignancies.

Professor John Caldwell, Dean of the Faculty of Medicine, said: “Liverpool plays a vital role in the development of new treatments for cancer – 15.2% of cancer patients in the area are recruited to trials – one of the highest rates in the UK. The merge with our cancer research partners will allow us to double the number of patients to early phase clinical trials as well as increase the capacity for treating cancer patients.”

The developments are part of an overall £20 million investment in cancer research and follow the recent launch of the University’s School of Cancer Studies – a newly created department focusing entirely on research for new cancer treatments and therapies, incorporating the former Divisions of Surgery and Oncology, Haematology; and Pathology.

Joanna Robotham | alfa
Further information:
http://www.liv.ac.uk

More articles from Health and Medicine:

nachricht Organ-on-a-chip mimics heart's biomechanical properties
23.02.2017 | Vanderbilt University

nachricht Researchers identify cause of hereditary skeletal muscle disorder
22.02.2017 | Klinikum der Universität München

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Safe glide at total engine failure with ELA-inside

On January 15, 2009, Chesley B. Sullenberger was celebrated world-wide: after the two engines had failed due to bird strike, he and his flight crew succeeded after a glide flight with an Airbus A320 in ditching on the Hudson River. All 155 people on board were saved.

On January 15, 2009, Chesley B. Sullenberger was celebrated world-wide: after the two engines had failed due to bird strike, he and his flight crew succeeded...

Im Focus: Breakthrough with a chain of gold atoms

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

Im Focus: DNA repair: a new letter in the cell alphabet

Results reveal how discoveries may be hidden in scientific “blind spots”

Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...

Im Focus: Dresdner scientists print tomorrow’s world

The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.

The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...

Im Focus: Mimicking nature's cellular architectures via 3-D printing

Research offers new level of control over the structure of 3-D printed materials

Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Booth and panel discussion – The Lindau Nobel Laureate Meetings at the AAAS 2017 Annual Meeting

13.02.2017 | Event News

Complex Loading versus Hidden Reserves

10.02.2017 | Event News

International Conference on Crystal Growth in Freiburg

09.02.2017 | Event News

 
Latest News

New pop-up strategy inspired by cuts, not folds

27.02.2017 | Materials Sciences

Sandia uses confined nanoparticles to improve hydrogen storage materials performance

27.02.2017 | Interdisciplinary Research

Decoding the genome's cryptic language

27.02.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>